|
|||
|
|||
|
|||
|
|||
|
Strange targets: scientists, doctors, nurses, caregivers
|
Political partisans have picked a peculiar target in scorning public health professionals, including those at the Centers for Disease Control and Prevention and in state and local health agencies. The doctors, nurses, counselors, researchers, statisticians, and educators who pursue careers in this field make a commitment to improving the health of others. They investigate outbreaks of communicable and infectious diseases, as well as taints to the nation’s food, water, and air. Their work can be stressful and demanding, often occurring in uncertain and risky circumstances — not to mention in pursuit of remedies under significant time and resource constraints. They may put themselves and their loved ones at heightened risk with their exposure to the sick, injured, dying, and dead. They often may be responding in emergencies and crises near and far, especially when others may be heading their opposite direction — to secure the safety and well-being of their own loved ones. Many of the experts in this field, employed by the government, may accrue modest benefits after long service. But they often do not earn salaries that are close to what they might enjoy in the private sector with their comparable education (often including advanced degrees), experience, and accomplishments. As noted health journalist Laurie Garrett reported in an Opinion article for CNN: “[M]ost scientists and physicians working in HHS make less than $170,000 a year. I scrutinized nearly 1,000 pages of payroll listings at the Department of Health and Human Services and found few CDC employees who earn more than $150,000 annually. Some make considerably more than that, thanks to Title 42, a policy that gives federal agencies flexibility on salary limits in order to lure outstanding scientists and other professionals into government work. Nearly all of those scientists are classified as Medical Specialists, 138 of whom earn more than $250,000. All but 13 work at the National Institutes of Health, engaging in basic scientific research. “Just two individuals make more than $350,000, ranking them the most highly paid federal employees after the President (who is paid $400,000): Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, and Rachel Sherman, deputy commissioner of the Food and Drug Administration. Having run NIAID since 1984, Fauci is the longest serving Institute director in NIH history. He has been an adviser to five presidents, architect of the HIV program PEPFAR, the 24th most-cited scientist in history and recipient of every major biomedical award besides the Nobel Prize, including the Presidential Medal of Freedom and the National Medal of Science.” By way of comparison, the average annual pay pre-pandemic) for an orthopedist in private practice was $511,000, while plastic surgeons were paid $479,000, and cardiologists received $438,000. The American Association of Pharmaceutical Scientists reported that the mean total compensation for its reporting members in 2019 was $193,400. Public health staffers say they enjoy serving others and helping communities and working to advance their health and well-being. But this is an area of health care that always struggles with under- or roller-coaster-funding. The money and resources flow during crises, then they vanish. As a news article noted: “Since 2010, spending on state public health departments has dropped 16% per capita, and the amount devoted to local health departments has fallen 18%, according to [an analysis by two news organizations.] At least 38,000 state and local public health jobs have disappeared since the 2008 recession, leaving a skeleton workforce for what was once viewed as one of the world’s top public health systems.” In seeking to assist under served and neglected individuals and communities, public health officials often toil on behalf of unpopular populations — the poor, minorities, the physically and mentally ill, and those with substance problems. Public health officials may impose safeguards that can aggravate the public, as they have since at least the time that authorities in ports battled the black plague by forcing crews to stay aboard ships. Still, as the independent Kaiser Health News service and the Associated Press reported, public health pros have been subjected to unusual public ire during the coronavirus pandemic: “Vilified, threatened with violence or in some cases suffering from burnout, dozens of state and local public health officials around the U.S. have resigned or have been fired amid the coronavirus outbreak, a testament to how politically combustible masks, lockdowns and infection data have become … A review by KHN and The Associated Press finds [as of early August that] at least 49 state and local public health leaders have resigned, retired, or been fired since April across 23 states. The list has grown by more than 20 people since the AP and KHN started keeping track in June.” The reporters delved into the expert exodus, reporting: “Many of the firings and resignations have to do with conflicts over mask orders or shutdowns to enforce social distancing … Despite the scientific evidence that such measures help prevent transmission of the coronavirus, many politicians and others have argued they are not needed, no matter what health experts tell them. ‘It’s not a health divide; it’s a political divide,’ [said Lori Tremmel Freeman, CEO of the National Association of County and City Health Officials]. Some health officials said they were stepping down for family reasons, and some left for jobs at other agencies … Some …were ousted because of what higher-ups said was poor leadership or a failure to do their job. Others have complained that they were overworked, underpaid, unappreciated or thrust into a pressure-cooker environment.” The damages occurring to the public health field will not only harm the current battle against the coronavirus but also Americans well-being in the days ahead, Tom Inglesby, director of the UPMC Center for Health Security at Johns Hopkins, told the reporters: “Inglesby said it was deeply concerning that public health officials who told ‘uncomfortable truths’ to political leaders had been removed. ‘That’s terrible for the national response because what we need for getting through this, first of all, is the truth. We need data, and we need people to interpret the data and help political leaders make good judgments.’” |
FDA had plentiful issues already
|
Strange times can create unusual circumstances. This newsletter includes an example that may be startling to some: Yours truly writing kind words and in defense of the federal Food and Drug Administration as political partisans carve into the agency and its work. This position has its sound reasoning. The FDA, as the public’s federal watchdog, inarguably needs to be more (not less) rigorous in its oversight of Big Pharma and medical-device makers. And taxpayers need to discourage intervention by politicians, even in the name of a pandemic emergency, to push pro-industry policy making and practical changes at the FDA to speed medications and devices to the market. Big Pharma has howled for some time now at politicians, regulators, and the public for fixes to the oversight system — and the industry has gotten its way. But as NPR reported, based on a study posted online on the JAMA Network: “The [FDA] has gotten faster at approving new prescription drugs over the past four decades, but the evidence it relies on in making those decisions is getting weaker … As a result, there are more … treatments on the market but less proof that they are safe and effective.” Jonathan Darrow, a lawyer with Harvard Medical School’s Program on Regulation, Therapeutics, and Law and lead author of the JAMA work that scrutinized FDA drug policies and practices for the quarter century since 1983, told public radio that “”There has been a gradual erosion of the evidence that’s required for FDA approval.” As a result, patients and physicians “should not expect that new drugs will be dramatically better than older ones.” Darrow and colleagues at Boston hospitals and research institutions found that “half of recent new drug approvals were based on only one pivotal clinical trial instead of the two or more that used to be the norm … And the reliance on surrogate measures — stand-ins for presumed patient benefits — has increased. In the case of cancer drugs, a surrogate measure could be shrinkage of tumors instead of improvements in survival after treatment,” NPR reported. By accepting less evidence, federal regulators have stepped back from their tough oversight over prescription drugs, so that products in 2018 got through reviews in 10 months versus the 2.1 years it took in the late 1980s and 1990s. And that was before Big Pharma started spending big on lobbying to persuade members of Congress that drug approvals needed to be sped up, so innovations could benefit patients sooner. The argument had urgency, following too many medical experts’ lead-footed response to the HIV-AIDS crisis. But the Republican-dominated Congress has, for example, sent a misguided signal to regulators at the FDA by tying increasing sums in their budget to fees the agency collects from Big Pharma for ensuring its products are safe and effective. With medical devices, investigations by various media outlets have raised serious doubts about the stringency and the transparency with which the FDA conducts its oversight of a booming industry. My blog long has detailed how costly lawsuits must accrue into big numbers of cases before the agency responds to problem products. I’ve told my readers how — whoops! — a media organization found that the FDA had stashed huge numbers of aggregated product complaints in undisclosed files. The agency offered an unacceptable “reform” of its medical-device oversight, effectively allowing new devices to bootstrap themselves on to the market simply by showing “substantial equivalence” to existing products, some decades old and, critics said, considerably different. Stat, the medical and scientific news site, quoted Holly Fernandez Lynch, a health policy expert and University of Pennsylvania professor of medical ethics, and her savvy take on the pandemic and its potential to worsen and to create regulatory issues for the FDA: “It’s a political agency, and it has a political appointee at the head, but it has maintained a reputation for decades of being a science-focused agency. There have definitely been slip-ups, but the level of interference that we’re seeing from the White House is so concerning.” Other experts quoted in the Stat article argued that it can be to easy to expand “exigent” or “emergency” use of raw political power to influence FDA decisions on prescription drugs, treatments, and medical devices. “Why not? Why not try things? What have we got to lose?” President Trump has asserted as he has muscled the public and regulators to, frankly, become guinea pigs for several different coronavirus medications or treatments. He and other Republicans also have said the push for nostrums in the pandemic is akin to dubious “right to try” laws that they say can give terminal patients hope by allowing Big Pharma to supply them unproven drugs as a last resort. But cancer patients already confront increasingly tough choices with an increasing array of costly drug treatments that may have minimal benefit with the quality or length of their lives. Drug makers have gotten skilled at persuading FDA regulators to approve cancer drugs based on “surrogate endpoints,” technical findings, for example, that medications may slow tumor growth without halting a cancer or bettering or extending patients’ lives. Front-line clinicians, especially early in the pandemic, may have thrown the kitchen sink at coronavirus patients. But such approaches can mask which therapies are most beneficial, and politically forced approvals for drugs and treatments may block the public and researchers from the hard work of rigorous, randomized clinical trials that are the gold standard in determining the safety and effectiveness of medications and therapies. The issue of how to not only protect the FDA from inappropriate political influence while also ensuring it functions well is complicated. Those interested may wish to take a look at a 2019 proposal from seven former commissioners, arguing that a key step in improving the agency and its work would be to remove it from the sprawling Health and Human Services department and make it an independent operation. |
Recent Health Care Blog Posts |
Here are some recent posts on our patient safety blog that might interest you:
|
WE’RE LOOKING AHEAD TO A HEALTHY 2021!
|
Sincerely, Patrick Malone |